• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用趋化因子系统将 CAR-T 细胞归巢到实体肿瘤中。

Harnessing the chemokine system to home CAR-T cells into solid tumors.

机构信息

Chemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, SA 5005, Australia.

Carina Biotech, Innovation and Collaboration Centre, The University of South Australia, Adelaide, SA 5000, Australia.

出版信息

Cell Rep Med. 2022 Feb 28;3(3):100543. doi: 10.1016/j.xcrm.2022.100543. eCollection 2022 Mar 15.

DOI:10.1016/j.xcrm.2022.100543
PMID:35492880
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9040186/
Abstract

CAR-T cell therapy has been heralded as a breakthrough in the field of immunotherapy, but to date, this success has been limited to hematological malignancies. By harnessing the chemokine system and taking into consideration the chemokine expression profile in the tumor microenvironment, CAR-T cells may be homed into tumors to facilitate direct tumor cell cytolysis and overcome a major hurdle in generating effective CAR-T cell responses to solid cancers.

摘要

嵌合抗原受体 T 细胞疗法被誉为免疫疗法领域的一项突破,但迄今为止,这种成功仅限于血液系统恶性肿瘤。通过利用趋化因子系统并考虑肿瘤微环境中的趋化因子表达谱,CAR-T 细胞可能归巢到肿瘤中,以促进直接肿瘤细胞细胞溶解,并克服产生针对实体瘤的有效 CAR-T 细胞反应的主要障碍。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6820/9040186/a0ba7e873c5c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6820/9040186/21f142e5acc0/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6820/9040186/9cbc324dc903/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6820/9040186/a0ba7e873c5c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6820/9040186/21f142e5acc0/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6820/9040186/9cbc324dc903/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6820/9040186/a0ba7e873c5c/gr2.jpg

相似文献

1
Harnessing the chemokine system to home CAR-T cells into solid tumors.利用趋化因子系统将 CAR-T 细胞归巢到实体肿瘤中。
Cell Rep Med. 2022 Feb 28;3(3):100543. doi: 10.1016/j.xcrm.2022.100543. eCollection 2022 Mar 15.
2
Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors.肿瘤微环境免疫抑制:CAR T 细胞在实体瘤中进展的障碍。
Cells. 2022 Nov 16;11(22):3626. doi: 10.3390/cells11223626.
3
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.实体瘤的嵌合抗原受体 T 细胞:在肿瘤微环境中寻找、浸润和存活的新策略。
Front Immunol. 2019 Feb 5;10:128. doi: 10.3389/fimmu.2019.00128. eCollection 2019.
4
CAR T Cell Therapy for Solid Tumors.嵌合抗原受体 T 细胞疗法治疗实体瘤。
Annu Rev Med. 2017 Jan 14;68:139-152. doi: 10.1146/annurev-med-062315-120245. Epub 2016 Nov 17.
5
Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells.逆转趋化因子/趋化因子受体不匹配以增强 CAR-T 细胞的抗肿瘤疗效。
Immunotherapy. 2022 Apr;14(6):459-473. doi: 10.2217/imt-2021-0228. Epub 2022 Mar 2.
6
CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.嵌合抗原受体 T 细胞与溶瘤病毒:联合攻克实体瘤挑战。
Front Immunol. 2018 Oct 23;9:2460. doi: 10.3389/fimmu.2018.02460. eCollection 2018.
7
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment.通过靶向肿瘤微环境来增强 CAR-T 细胞在实体瘤中的疗效。
Cell Mol Immunol. 2021 May;18(5):1085-1095. doi: 10.1038/s41423-021-00655-2. Epub 2021 Mar 30.
8
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?嵌合抗原受体 T 细胞疗法治疗实体瘤:光明的未来还是黑暗的现实?
Mol Ther. 2020 Nov 4;28(11):2320-2339. doi: 10.1016/j.ymthe.2020.09.015. Epub 2020 Sep 16.
9
Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.通过 CAR T 细胞过继转移来操纵肿瘤微环境。
Mamm Genome. 2018 Dec;29(11-12):739-756. doi: 10.1007/s00335-018-9756-5. Epub 2018 Jul 9.
10
Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.当前增加嵌合抗原受体T细胞疗法对实体瘤患者益处的临床证据及潜在解决方案。
Oncoimmunology. 2020 Jun 10;9(1):1777064. doi: 10.1080/2162402X.2020.1777064.

引用本文的文献

1
Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions.实体瘤中CAR-T细胞疗法的进展:现状与未来方向
Cancers (Basel). 2025 Sep 3;17(17):2898. doi: 10.3390/cancers17172898.
2
Scvi-hub: an actionable repository for model-driven single-cell analysis.Scvi-hub:一个用于模型驱动单细胞分析的可操作资源库。
Nat Methods. 2025 Sep 8. doi: 10.1038/s41592-025-02799-9.
3
hCCL19-expressing recombinant Newcastle disease virus boosts CAR T cell infiltration and efficacy in solid tumor.表达hCCL19的重组新城疫病毒可促进CAR-T细胞在实体瘤中的浸润并提高其疗效。

本文引用的文献

1
CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment.CXCR6 将细胞毒性 T 细胞定位在肿瘤微环境中,以接收关键的存活信号。
Cell. 2021 Aug 19;184(17):4512-4530.e22. doi: 10.1016/j.cell.2021.07.015. Epub 2021 Aug 2.
2
Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer.人透明质酸酶 PH20 增强了针对胃癌的间皮素特异性 CAR-T 细胞的抗肿瘤活性。
Front Immunol. 2021 Jul 13;12:660488. doi: 10.3389/fimmu.2021.660488. eCollection 2021.
3
Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors.
J Immunother Cancer. 2025 Jul 25;13(7):e011783. doi: 10.1136/jitc-2025-011783.
4
Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives.推进基于嵌合抗原受体(CAR)的实体瘤细胞疗法:挑战、治疗策略及展望
Mol Cancer. 2025 Jul 7;24(1):191. doi: 10.1186/s12943-025-02386-8.
5
[CAR T cells in solid tumors: resistance mechanisms].[实体瘤中的嵌合抗原受体T细胞:耐药机制]
Inn Med (Heidelb). 2025 Jun 25. doi: 10.1007/s00108-025-01943-z.
6
Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging.通过光学和靶向前列腺特异性膜抗原(PSMA)的正电子发射断层扫描(PET)成像开发原位嵌合抗原受体(CAR)-T细胞方案。
Proc Natl Acad Sci U S A. 2025 Jun 17;122(24):e2504950122. doi: 10.1073/pnas.2504950122. Epub 2025 Jun 10.
7
Reciprocal Modulation of Tumour and Immune Cell Motility: Uncovering Dynamic Interplays and Therapeutic Approaches.肿瘤与免疫细胞运动的相互调节:揭示动态相互作用及治疗方法
Cancers (Basel). 2025 May 1;17(9):1547. doi: 10.3390/cancers17091547.
8
Targeting Intracellular Innate RNA-Sensing Systems Overcomes Resistance to CAR T-cell Therapy in Solid Tumors.靶向细胞内天然RNA传感系统可克服实体瘤对CAR-T细胞疗法的耐药性。
Cancer Res. 2025 Jul 15;85(14):2679-2693. doi: 10.1158/0008-5472.CAN-24-3425.
9
Encoding and decoding selectivity and promiscuity in the human chemokine-GPCR interaction network.人类趋化因子 - G 蛋白偶联受体相互作用网络中的编码与解码选择性及混杂性
Cell. 2025 Jun 26;188(13):3603-3622.e27. doi: 10.1016/j.cell.2025.03.046. Epub 2025 Apr 23.
10
Engineering sonogenetic EchoBack-CAR T cells.工程化超声基因回声CAR-T细胞。
Cell. 2025 May 15;188(10):2621-2636.e20. doi: 10.1016/j.cell.2025.02.035. Epub 2025 Apr 2.
联合肿瘤靶向招募和免疫抑制保护可增强 CAR T 细胞在实体瘤中的疗效。
Sci Adv. 2021 Jun 9;7(24). doi: 10.1126/sciadv.abi5781. Print 2021 Jun.
4
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.携 CX-C 趋化因子受体 6 的 T 细胞增强了对胰腺肿瘤的过继细胞治疗。
Nat Biomed Eng. 2021 Nov;5(11):1246-1260. doi: 10.1038/s41551-021-00737-6. Epub 2021 Jun 3.
5
The principles of directed cell migration.定向细胞迁移的原理。
Nat Rev Mol Cell Biol. 2021 Aug;22(8):529-547. doi: 10.1038/s41580-021-00366-6. Epub 2021 May 14.
6
Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models.三特异性 CD19-CD20-CD22 双靶点 CAR-T 细胞在临床前模型中消除抗原异质性 B 细胞肿瘤。
Sci Transl Med. 2021 Mar 24;13(586). doi: 10.1126/scitranslmed.abc6401.
7
Cancer-associated fibroblast-derived SDF-1 induces epithelial-mesenchymal transition of lung adenocarcinoma via CXCR4/β-catenin/PPARδ signalling.癌相关成纤维细胞衍生的 SDF-1 通过 CXCR4/β-catenin/PPARδ 信号诱导肺腺癌上皮间质转化。
Cell Death Dis. 2021 Feb 26;12(2):214. doi: 10.1038/s41419-021-03509-x.
8
FDA approves fourth CAR-T cell therapy.美国食品药品监督管理局批准第四种嵌合抗原受体T细胞疗法。
Nat Rev Drug Discov. 2021 Mar;20(3):166. doi: 10.1038/d41573-021-00031-9.
9
Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma.嵌合抗原受体 T 细胞靶向 GD2 治疗神经母细胞瘤的抗肿瘤活性及无靶外毒性。
Sci Transl Med. 2020 Nov 25;12(571). doi: 10.1126/scitranslmed.abd6169.
10
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.双特异性抗 CD20、抗 CD19 CAR T 细胞治疗复发 B 细胞恶性肿瘤:1 期剂量递增和扩展试验。
Nat Med. 2020 Oct;26(10):1569-1575. doi: 10.1038/s41591-020-1081-3. Epub 2020 Oct 5.